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 Abstract 
Context: Given the highly variable behavior and clinical course of prostate cancer (PCa) and 
the multiple available treatment options, a personalized approach to oncologic risk 
stratification is important. Novel genetic approaches offer additional information to improve 
clinical decision making. 
Objective: To review the use of genomic biomarkers in the prognostication of PCa outcome 
and prediction of therapeutic response. 
Evidence acquisition: Systematic literature review focused on human clinical studies 
reporting outcome measures with external validation. The literature search included all 
Medline, Embase, and Scopus articles from inception through July 2014. 
Evidence synthesis: An improved understanding of the genetic basis of prostate 
carcinogenesis has produced an increasing number of potential prognostic and predictive 
tools, such as transmembrane protease, serine2:v-ets avian erythroblastosis virus E26 
oncogene homolog (TMPRSS2:ERG) gene fusion status, loss of the phosphatase and tensin 
homolog (PTEN) gene, and gene expression signatures utilizing messenger RNA from tumor 
tissue. Several commercially available gene panels with external validation are now 
available, although most have yet to be widely used. The most studied commercially 
available gene panels, Prolaris, Oncotype DX Genomic Prostate Score, and Decipher, may be 
used to estimate disease outcome in addition to clinical parameters or clinical nomograms. 
ConfirmMDx is an epigenetic test used to predict the results of repeat prostate biopsy after an 
initial negative biopsy. Additional future strategies include using genetic information from 
circulating tumor cells in the peripheral blood to guide treatment decisions at the initial 
diagnosis and at subsequent decision points. 
Conclusions: Major advances have been made in our understanding of PCa biology in recent 
years. Our field is currently exploring the early stages of a personalized approach to augment 
 traditional clinical decision making using commercially available genomic tools. A more 
comprehensive appreciation of value, limitations, and cost is important. 
Patient summary: We summarized current advances in genomic testing in prostate cancer 
with a special focus on the estimation of disease outcome. Several commercial tests are 
currently available, but further understanding is needed to appreciate the potential benefits 
and limitations of these novel tests. 
 1. Introduction 
Prostate cancer (PCa) is the most common urologic malignancy and the second leading cause 
of male cancer-related deaths in many developed countries [1]. A personalized approach, 
including the prediction of individual patient outcomes and therapeutic responses, is 
important in all cancers but especially for PCa, given the variability in disease behavior, the 
diversity of treatment options, and the risk of treatment-related impairment of quality of life 
[2]. Novel genomic technologies, such as microarray analyses and next-generation 
sequencing, have improved our understanding of the biology of PCa. Consequently, the 
scientific community is faced with an explosion of data, new challenges, and opportunities in 
biomarker discovery and validation [3]. With improved approaches to biomarker research, 
combined with lower cost and more efficient techniques, the potential of a personalized 
genomic approach for clinical decision making has recently been made possible. 
Among the most prominent topic in PCa genetics is the characterization of somatic genomic 
alterations in tumor tissue for the prognosis and prediction of treatment response. Novel 
approaches include genetic analyses from peripheral blood, either germline analyses or 
characterization of DNA/RNA from circulating tumor cells (CTCs), or free circulating 
nucleic acids. The genetic landscape, key genetic alterations, epigenetic events, and 
microRNAs (miRNAs) in PCa have been reviewed [4±7].  
In this paper, we focus on the value of genomic markers in the personalized prediction of PCa 
outcome and response to various therapeutic interventions. Due to the breadth of the topic 
and recent high-quality reviews, we have specifically focused on genomic tests that are 
already available or approaching the point of clinical use [4±10]. 
2. Evidence acquisition 
A literature review was performed according to the Preferred Reporting Items for Systematic 
Reviews and Meta-analysis criteria. Figure 1 presents the process of identifying references 
 [11]. The first author performed a Medline, Embase, and Scopus search of all articles from 
inception through July 2014 using the keywords prostate cancer and genetics and prognostic. 
Genetic PCa outcome studies with the following criteria were prioritized: human clinical 
studies, clinical outcome end points (biochemical progression, clinical progression, disease-
specific survival [DSS], and overall survival), and external validation cohorts. Articles of 
interest and review articles were surveyed and verified for any missed reports. All authors 
oversaw and approved the final literature review and selection.  
3. Evidence synthesis 
3.1. Clinically relevant genes and genetic pathways in prostate cancer 
3.1.1. TMPRSS2:ERG fusion 
In 2005, Tomlins and coworkers reported a novel frequent chromosomal rearrangement in 
PCa, a fusion between transmembrane protease, serine 2 (TMPRSS2) gene and v-ets avian 
erythroblastosis virus E26 oncogene homolog (ERG) gene or other ETS (E26 transformation 
specific) transcription factors, until now recognized as the most frequent gene-specific 
alterations in PCa [12,13]. ETS fusion±type cancers are believed to represent a genetically 
distinct subset of PCa characterized by deletions of the phosphatase and tensin homolog 
(PTEN) gene and of chromosome 3p, whereas deletions of 5q and 6q prevail in fusion-
negative cancers [14±17]. Although gene fusions in general, and specifically ETS fusions, 
have been associated with the early onset of PCa [18,19], the clinical utility of the gene 
fusion as a prognostic or predictive tool is still unclear. 
Many studies have investigated the association of TMPRSS2:ERG fusion status and outcome 
in PCa (Table 1). Ten studies reported the prognostic value of the gene fusion in radical 
prostatectomy (RP) cohorts [19±28]. In 6 of the 10 studies, TMPRSS2:ERG fusion status was 
not associated with outcome after surgery [19,21,22,24,27,29]. In one study, patients with 
rearrangement had an 8.6-fold increased risk for biochemical recurrence (BCR), and in 
 another study, fusion status was predictive of BCR risk in a small selected cohort of Gleason 
7 cases [23,28]. In contrast, one study demonstrated lower BCR risk after RP among patients 
with the TMPRSS2:ERG fusion [25]. Overall, a meta-analysis including 5074 men following 
RP found no significant association with BCR or lethal disease [24]. One study investigated 
the outcome after intensity-modulated radiation therapy but found no association between 
fusion status and BCR. 
Nevertheless, when investigated beyond the gene fusion status, some additional prognostic 
information has been reported. FitzGerald and coworkers did not observe a significant 
association between TMPRSS2:ERG fusion status and outcome, but patients with increased 
copy numbers of the fusion gene showed poorer survival [20]. Furthermore, Boormans and 
coworkers reported fusion gene transcript-specific data; that is, TMPRSS2:ERG (Exon0)±
ERG fusion was associated with a lower risk of BCR compared with Exon1 fusion [26]. 
In contrast to studies in cohorts treated with curative intent, the presence of TMPRSS2:ERG 
fusion had an independent negative impact on outcome in four watchful waiting (WW) 
cohorts and on a cohort of patients with castration-resistant PCa (CRPC) undergoing 
palliative transurethral resection of the prostate (TURP) [30±34]. Therefore, one could 
speculate that TMPRSS2:ERG fusion status is a predictor of response to androgen-deprivation 
therapy (ADT). However, this hypothesis was not supported by Boormans and coworkers. 
They found no association between TMPRSS2:ERG fusion status with ADT response or 
outcome in PCa patients with lymph node metastases (N1) treated with ADT [35]. Similarly, 
Leinonen and coworkers found no association between TMPRSS2:ERG fusion status and 
outcome among ADT-treated patients [36]. A recent study investigated TMPRSS2:ERG 
fusion status from biopsies of 265 active surveillance (AS) patients and found that 
TMPRSS2:ERG fusion-positive patients had a significantly higher risk of disease progression 
(hazard ratio: 2.45) compared with fusion-negative patients [37]. However, another study of 
 PCa patients on AS showed that urinary TMPRSS2:ERG and the prostate cancer antigen 3 
(PCA3) gene were not significant independent predictors of biopsy reclassification on 
multivariable analysis [38].  
In addition to its own potential prognostic value, TMPRSS2:ERG fusion status may modify 
the interpretation of other PCa biomarkers in outcome prediction. Barwick and coworkers 
noted that the expression of several genes was affected by TMPRSS2:ERG fusion status [39]. 
In fusion-positive cases, upregulated genes were related to mismatch base repair and histone 
deacetylation, whereas genes involved in insulinlike growth factor (IGF) and Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) signaling were 
downregulated [39]. In addition Brase et al showed the TMPRSS2-ERG gene fusion results in 
the modulation of certain transcriptional patterns and well-known PCa biomarkers like 
CRISP3 and TDRD1 that were found to be associated with the gene fusions [40]. Karnes and 
coworkers did not detect a direct association between TMPRSS2:ERG fusion status and 
outcome, but classifying the cohort according to TMPRSS2:ERG fusion status had a 
significant impact on the predictive value of other investigated markers [41]. Similarly, 
TMPRSS2:ERG fusion status was noted to significantly affect the prognostic value of a 36-
gene expression panel [42]. Taken together, although the true prognostic value of 
TMPRSS2:ERG fusion status itself has not been proven, fusion status is a key genomic event 
and should be taken into consideration when the prognostic value of other genomic events is 
investigated.  
3.1.2. PTEN 
PTEN deleted on chromosome 10 is one of the most frequently mutated genes in human 
cancer. It dephosphorylates lipid-signaling intermediates, resulting in deactivation of PI3K 
signaling, and thus controls proliferation and growth [43]. In a landmark study by Saal and 
coworkers in 2007, PTEN loss was associated with poor outcome in a variety of cancers 
 including PCa and cancer of the urinary bladder [44]. The prognostic value of PTEN in PCa 
was investigated in a few studies (Table 2). In 649 PCa patients, Leinonen and coworkers 
demonstrated a higher frequency of PTEN loss in more advanced cases (CRPC compared 
with RP cases) and that PTEN loss was associated with shorter progression-free survival time 
but notably only in ERG-positive cases [45]. Similarly, in another study the prognostic value 
of PTEN was clearly associated with TMPRSS2:ERG fusion status [46]. In a large cohort 
including 4699 RP specimens and 57 CRPC cases, Krohn and coworkers also demonstrated 
that PTEN loss was associated with adverse clinicopathologic factors and a higher risk of 
BCR [47]. Contrary to the findings of Leinonen et al, PTEN had similar prognostic utility in 
ERG-positive and -negative cases. In a study among conservatively managed PCa patients by 
Reid et al, PTEN loss without TMPRSS2:ERG fusion was associated with poor cancer-
specific survival, which is in contrast to other studies where PTEN loss and TMPRSS2:ERG 
fusion defined the patients with the worst survival [48].  
As yet, the predictive role of PTEN status in castration-sensitive and resistant cancers has 
only been evaluated in one study [49]. McCall et al investigated PTEN status by fluorescent 
in situ hybridization and immunohistochemistry in matched tumor pairs (one before and one 
after ADT relapse). They noted that loss of PTEN expression in the nucleus was 
independently associated with poor DSS but only in the castration-sensitive tumor specimens. 
PTEN-negative tumors were recently shown to have shorter survival in the post-docetaxel 
abiraterone treatment setting compared with cases with preserved PTEN expression [50]. 
3.2. Gene/expression panels 
Cancer is a complex disease, and it is unlikely a single genetic abnormality will sufficiently 
reflect events in a tumor to give enough prognostic information for clinical decisions. Most 
authors suggest that a combination of multiple genetic markers will be necessary. Panels 
evaluate differential expression of multiple genes between patient groups of interest (eg, 
 biochemical relapse vs no relapse after RP). These panels may be selected using prior 
knowledge by including key carcinogenic pathways in PCa (eg, cell cycle regulation, 
apoptosis) [51] or filtered from thousands of unselected genes to distinguish gene-phenotype 
correlates [52±54]. 
These studies face many challenges including the risk of chance associations given the 
quantity of data. Therefore experienced biostatistical support and appropriate external 
validations are essential before widespread clinical applications can be considered. Approved 
principles of study design include blinded marker analyses and randomly selected cases (in 
retrospective studies) [55]. Study reporting may be negatively affected by several potential 
biases, and therefore adherence to standard criteria, such as Reporting Recommendations for 
Tumor Marker Prognostic Studies (REMARK), is essential for providing evidence on the 
clinical utility of biomarkers in oncology [56]. The biomarkers to be included in clinical 
decision making have to provide additional independent prognostic information or additive 
value together with established clinical and pathologic variables in a multivariate setting like 
the Memorial Sloan Kettering Cancer Center or Cleveland Clinic nomograms or Cancer of 
the Prostate Risk Assessment Postsurgical (CAPRA-S) risk stratification for PCa. 
3.2.1. Discovery studies  
Table 3 lists studies reporting the prognostic value of gene/expression panels for clinically 
significant end points. Most have investigated prediction of outcome after RP using different 
end points, such as risk for biochemical failure [42,51,52,57,58], metastatic progression 
[52,53,59,60], and DSS [54,60,61]. A few studies investigated TURP tissue to predict the 
outcome of men undergoing conservative treatment [51,62,63].  
The design of discovery studies included several approaches: single- and multicenter studies 
and correlation of gene panel data to outcomes of the full cohort or selected subgroups 
[42,51,52,57,58,62] or a case-control population selected on a particular outcome 
 [53,59,60,63]. All except one study reported that the applied expression panel offered 
significant prognostic information in the particular study cohort. Sboner and coworkers 
studied TURP tissue from WW patients, but the gene signature failed to improve the 
prognostic value of a model including clinicopathologic parameters [63]. Studies have 
utilized different methodological approaches to assess the value of genomic tests. These 
approaches included traditional statistical methods (survival analyses, multivariable models 
with other clinicopathologic variables, and receiver operating characteristic analysis) [42,51±
53,59,60,62±64]. In some studies, results from expression panels were combined with other 
variables or a nomogram to determine if genomic data added prognostic information above 
the baseline models [54,57,58,61,65].  
3.2.2. External validation studies 
A 46-gene expression panel (31 cell-cycle progression genes and 15 housekeeping genes) 
initially reported by Cuzick and coworkers in 2011 was validated in four studies and is 
commercially available as the Prolaris test (Myriad Genetics, Salt Lake City, UT, USA). The 
test was first validated from biopsy and TURP specimens in a conservatively managed 
cohort, and the gene panel significantly predicted PCa death in a multivariate model [66]. 
The panel was externally validated in two RP studies (one analyzing pre-RP biopsy tissue 
and one using RP tissue) including a total of >1300 patients and was noted to be an 
independent prognostic factor for BCR and metastatic progression [65,67]. When added to a 
multivariable score reflecting post-RP clinical and pathologic risk (CAPRA-S score) [68], the 
gene classifier provided incremental prognostic value beyond standard clinical models 
(concordance index for combined genetic/clinical model was 0.77 versus 0.73 for the clinical 
model alone) [65].  
A combined model incorporating CAPRA-S and a cell cycle progression score also 
 radiation therapy (EBRT) cohort, the panel was an independent prognostic factor after 
adjusting for clinical variables [69]. The potential impact of Prolaris was investigated in one 
study where physicians were surveyed about treatment recommendations in 305 men with 
newly diagnosed PCa [70]. In 65% of the cases, the treatment recommendation changed after 
the genetic test, and in 40% there was reduction in treatment burden (interventional treatment 
changed to noninterventional). Although this study shows genomic tests can have a 
significant impact on treatment decisions, follow-up data were not reported to determine the 
long-term impact of these changes in management. Furthermore, the test remains very 
expensive (approximately $3400), and available data on cost effectiveness are limited. 
In 2013 Erho et al reported in a case-control study that a 22-gene panel predicted survival 
after RP [53]. This panel has also been externally validated in multiple cohorts and is 
commercially available as the Decipher genetic test (GenomeDX Biosciences, Vancouver, 
BC, Canada). Four studies reported the utilization of this gene panel to predict BCR, 
metastatic progression, or DSS after RP plus or minus EBRT [61,71±73]. The prognostic 
accuracy was highest when the genomic classifier and clinical models (CAPRA-S) were 
combined [61]. In another study, including 85 high-risk RP patients, the 22-gene panel was 
the only variable associated with metastatic progression in a multivariable model and had a 
favorable net benefit compared with clinical models (CAPRA-S and Stephenson 
postoperative nomogram) [68,74] in decision-curve analysis [71,72]. The test also improved 
prediction of BCR and metastatic progression risk in a cohort of 139 men undergoing EBRT 
after RP [73]. The impact of Decipher was evaluated in a clinical utility study where 21 uro-
oncologists were presented 24 patient cases (12 potential candidates for adjuvant and 12 for 
salvage EBRT) and were asked for treatment recommendations with and without information 
from the genetic test [75]. The recommendation changed in 43% of the adjuvant cases and 
 53% in the salvage setting, suggesting a potentially significant impact on treatment decisions 
after RP. However, the long-term impact of these changes in management is unknown. 
Another commercially available test, Oncotype DX Genomic Prostate Score (GPS; Genomic 
Health Inc, Redwood City, CA, USA), is a 17-gene expression panel that has been 
investigated as a predictor for the risk of recurrence, PCa death, and especially adverse 
pathology at RP [54]. For the latter, biopsy tissue was used to derive a gene panel and 
estimate the risk of high-JUDGH*OHDVRQ + 3) and/or high-stage disease (pT3 or higher). 
The panel was validated in a cohort of 395 RP patients, and the Genomic Prostate Score was 
an independent predictor of unfavorable pathology in models including individual clinical 
parameters (age, prostate-specific antigen [PSA], clinical stage, and biopsy Gleason score) or 
a multivariable pretreatment clinical risk model (CAPRA score) [54]. The test was further 
recently validated on biopsies from 431 patients with very low-, low-, or intermediate-risk 
PCa. The test was significantly associated with adverse pathologic features and also 
independently predicted time to BCR after adjusting for risk as well as time to metastases 
[76]. 
It should be noted that although these three PCa expression panels include a total of 85 genes, 
there is virtually no overlap between the tests. The panels in Prolaris and Decipher have only 
one gene in common. Importantly, as yet there are no comparative data testing these panels in 
the same patient cohort. 
3.3. Epigenetic signature 
A comprehensive next-generation sequencing study of Gu and coworkers recently 
underscored the prognostic value of global- and gene-specific epigenetic alterations in PCa 
[77]. A methylation marker genetic test, ConfirmMDx (MDxHealth), utilizes methylation 
analysis of glutathione S-transferase pi 1 (GSTP1), adenomatous polyposis coli (APC), and 
Ras association (RalGDS/AF-6) domain family member 1 (RASSF1) genes from negative 
 biopsies to estimate the likelihood of a repeat biopsy also being negative [78]. The test 
achieved a 90% negative predictive value (NPV) within 30 mo of the initial biopsy. In a 
recent validation trial, 88% NPV was reported, and the test was the most significant predictor 
of biopsy results [79]. The impact of the epigenetic test on rebiopsy rates was recently 
surveyed in five centers, and among 138 patients with a negative ConfirmMDx assay, only 
six patients (4%) underwent repeat biopsies [80].  
3.4. Copy number variation 
Copy number variation (CNV) refers to gains or losses of certain areas of somatic DNA that 
potentially have carcinogenic consequences (eg, activation of oncogenes or inactivation of 
tumor suppressor genes) [4]. Overall, PCa is characterized by loss of genomic material [81]. 
The prognostic role of CNV may be analyzed with different approaches, by either 
investigating specific genetic gains or deletions, or by analyzing the overall burden of CNV. 
For example, Tsuchiya et al investigated specific chromosome 8 abnormalities, and loss of 
8p22 was associated with an increased risk of BCR and metastatic progression [82]. Liu et al 
studied the 20 most significant CNVs (15 deletions, 5 amplifications) in two RP cohorts and 
noted two CNVs (gain of area of v-myc avian myelocytomatosis viral oncogene homolog 
[MYC], deletion of PTEN) were significantly associated with PCa death [83]. Similar 
findings were reported in patients undergoing radiation therapy [84].  
Recent advances in high-throughput methodology have allowed investigations of the overall 
CNV burden and outcome. Taylor and coworkers analyzed RP cohorts for CNV utilizing 
unsupervised clustering and identified six patient clusters according to the degree of CNV. 
When analyzed for risk of BCR, CNV clusters had a significant association with outcome in 
univariate analysis [81]7KH³VLPSOHVW´DSSURDFKwas reported by Hieronymus and 
coworkers, who studied the association between percentage of CNV from intact somatic 
DNA and outcome after RP [85]. A significant difference was noted for BCR and metastatic 
 progression risks in SDWLHQWVZLWKDOWHUHGWXPRU'1$The degree of altered DNA was 
also an independent predictor of BCR on multivariable analysis of the whole cohort and a 
subcohort of Gleason 7 tumors.  
Paris and coworkers utilized array comparative genomic hybridization to identify specific 
DNA-based biomarkers (eg, loss at 8p23.2 and gain at 11q13.1). They suggested a combined 
set of 39 loci termed Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP). In the 
discovery study, the GEMCaP set of markers was associated with disease recurrence and 
metastasis [86]. Later the GEMCaP was demonstrated to offer additional prognostic 
information above the Kattan nomogram for disease recurrence in high-risk node-negative 
PCa cases after RP (nomogram accuracy 65% vs accuracy of nomogram and GEMCaP 78%) 
[87]. 
According to these studies, CNV analyses may have a prognostic role in PCa patients, but 
standardization of methods and additional validation studies are required before clinical 
applications may be planned. 
3.5. Genetic information from nucleic acids in peripheral blood and circulating tumor cells 
In addition to genetic information available from germline DNA and tumor tissue±derived 
DNA and RNA, peripheral blood is a potential source for genomic tumor characterization 
using free circulating nucleic acids, whole blood transcripts, or CTCs.  
In 2007 Bastian and coworkers reported an increasing quantity of circulating cell-free DNA 
was independently associated with the risk of BCR after RP [88]. In November 2012, two 
separate studies reported on gene expression profiling from blood RNA in patients with 
CRPC. Ross and coworkers examined a six-gene panel in CRPC patients with significantly 
improved prognostic value compared with a clinical model alone [89]. Olmos et al used a 
similar approach but divided the CRPC cohort into four groups according to microarray data 
analyzed from blood messenger RNA (mRNA) [90]. One patient group had a significantly 
 poorer survival, identified by a nine-gene panel. Specific miRNAs are found, not only in 
tumor tissue, but also in the plasma of PCa patients; miRNA-375 and miRNA-141 are 
reported to be associated with advanced disease [91].  
Recently Danila et al investigated the detection of CTCs and the expression of five genes 
frequently detected in PCa cells (but not in peripheral mononuclear cells) utilizing reverse 
transcriptase-polymerase chain reaction (RT-PCR) to detect transcripts from peripheral blood 
[92]. Both unfavorable CTC count (five or more cells) and detection of two or more gene 
transcripts had similar significant prognostic value for risk of PCa death, and when 
combined, additional prognostic value was demonstrated. With a similar approach, kallikrein-
related peptidase 3 (KLK3), PCA3, and TMPRSS2:ERG mRNA could be detected in the 
peripheral blood of CRPC patients but not in healthy controls [93]. Also, decreased 
expression levels of these genes were noted after docetaxel treatment, suggesting a potential 
role for treatment monitoring. 
Peripheral blood genetic information may also be useful to predict therapeutic response in 
CRPC. Recently, Antonarakis et al reported that a splice variant of the androgen receptor 
(AR-V7) could be detected in CTCs, and AR-V7±positive patients were less likely to respond 
to abiraterone or enzalutamide and had a poorer survival [94]. Confirmatory studies are 
awaited. In addition to specific genetic changes found in CTCs, the pretherapy CTC count 
has been demonstrated to predict response, and a decrease in the number of CTCs after 
therapy has greater predictive value than the classic 50% PSA decrease. This was observed 
after treatment with both docetaxel and abiraterone [95]. 
3.6. Discussion 
After years of intense research, we are finally witnessing progress in the field of PCa 
genomics and the emergence of commercially available genetic tests to assist clinical 
decision making. Because information on these tests is available not only to PCa specialists 
 but to all physicians and patients, it is important to understand their potential implications, 
optimal use, and limitations. Genetic prediction tools may also add significant costs to the 
PCa diagnostic and therapeutic algorithms, but these costs might be justified if indeed they 
lead to a reduction in unnecessary treatments for localized disease or a more appropriate 
selection of therapy for advanced disease.  
An important aspect of biomarker and genetics research is the heterogeneity of PCa both 
within a single tumor locus (intrafocal heterogeneity) and between different tumor deposits 
(interfocal heterogeneity) [96±98]. In addition to intra/interfocal heterogeneity, a field effect 
of genetic changes should also be considered because cancer-related genetic changes are also 
detected in benign areas of the same prostate [99]. This is the underlying premise of new tests 
designed to predict the risk of finding cancer on repeat biopsy for men with a negative biopsy 
[79], as well as biopsy-based tissue tests designed to predict whole-gland pathologic features. 
Genomic analysis of tumor tissue may aid in overcoming the challenges of sampling error 
and the variability of traditional pathologic grading. Standard pathologic evaluation, such as 
Gleason grading, is subjective and associated with significant inter- (and also intra-) observer 
variability that may have a significant impact on an individual patient¶s treatment 
recommendations [100].  
Genetic prognostication has potential applications in every step of PCa care. Commercially 
available epigenetic ConfirmMDx may be of value when repeat biopsies are considered after 
negative initial prostate biopsies. One of the most important is the appropriate selection of 
men to AS versus treatments with curative intent. To offer AS safely, the risk of 
underestimating the metastatic and local invasive potential of the individual tumor has to be 
minimized. In addition to improved biopsy techniques and imaging, genomic tests may be 
used to estimate the potential of tumor progression. The Oncotype DX Genomic Prostate 
Score was investigated in this setting and found to provide additional information to clinical 
 parameters and nomograms. Even after RP, the risk of recurrence and metastatic progression 
is highly variable, and the addition of genomic information to traditional variables appears to 
improve prognostic accuracy modestly. 
All three commercially available gene panels described in detail in this review (Prolaris, 
Decipher, and Oncotype DX Genomic Prostate Score) have been evaluated in terms of 
potential prognostic value after RP. The future will tell if this additional information is 
considered sufficient by the urologic community and PCa patients to change practice. 
Although clinical studies have suggested potential benefits with these tests, real clinical use 
and long-term data are needed to judge the added value.  
In addition to general prognostic information, prediction of response to specific treatment 
modalities (eg, adjuvant/salvage radiation, ADT, novel systemic agents) is of great 
importance. Due to an ever-expanding number of treatment options in CRPC, involving very 
different mechanisms and significant costs, there is a great need for markers to predict 
therapeutic response, typically seen in a minority of patients. With multiple sequentially 
delivered treatments, longitudinal monitoring of disease status is needed. In this setting, 
promise exists for sampling free circulating DNA and RNA or CTCs in peripheral blood, but 
further work is necessary to validate the findings before widespread clinical use. The issue of 
tumor cell heterogeneity in CTCs has yet to be explored. 
4. Conclusions 
Major advances in PCa genetics have occurred in recent years, and in the near future 
personalized genetic profiling of primary and metastatic tumor cells may become readily 
available for routine clinical decision making. Many new genetic-based tests are newly 
available or in late stages of clinical development, with potential applications in PCa 
decisions ranging from the need for repeat biopsy to initial treatment selection, decisions 
about secondary therapy, and selection of treatment for advanced disease. Greater 
 understanding of the potential long-term benefits and limitations of these tests is important, 
and how exactly they should be used in clinical practice to optimize decision making must be 
the subject of future prospective studies. 
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 Figure legend 
 
Fig. 1 ± Preferred Reporting Items for Systematic Reviews and Meta-analysis flow 
diagram presenting the steps of the literature search and the selection process of the 
articles. 
Table 1 Ȃ Studies reporting TMPRSS2:ERG fusion status and outcome after various treatment modalities 
Study 
No. of 
cases 
Tissue 
type 
Detection 
method 
Intervention 
ERG 
rearrangement 
rate, % 
ERG rearrangement association 
with clinical parameters 
Main results 
Radical prostatectomy and external-beam radiation therapy cohorts 
Steurer et al [19] 9567 RP FISH/IHC RP 54 NR 
Rearrangement associated with low-grade tumors in 
younger patients. ERG not associated with outcome. 
FitzGerald et al [20] 214 RP 
FISH, SNP 
genotyping 
RP 36 No 
Rearrangement not predictive of DSS, but cases with 
multiple fusion copies had trend toward poorer survival 
Gopalan et al [21] 521 RP FISH RP 46 Lower Gleason score Rearrangement not associated with outcome 
Hoogland et al [22] 509 RP IHC RP 55 Lower PSA 
ERG staining not associated with BCR or local recurrence 
risk 
Nam et al [23] 165 RP RT-PCR RP 49 No 
Rearrangement independently predictive of BCR (HR: 
8.6) 
Pettersson et al [24] 1292 RP IHC RP 49 Higher stage, lower PSA Rearrangement not associated with outcome 
Saramäki et al [25] 150 RP FISH RP 33 No 
Rearrangement independently associated with lower 
BCR risk 
Boormans et al [26] 112 RP RT-PCR RP 42 No 
TMPRSS2:ERG (Exon0)ȂERG fusion associated with lower 
risk of BCR compared with Exon1 fusion 
Minner et al [27] 2891 RP FISH/IHC RP 52 No ERG IHC positivity not predictive of BCR risk 
Nam et al [28] 26 RP RT-PCR RP 42 NA 
Rearrangement independently associated with 
recurrence risk 
Dal Pra et al [29] 
118 (IHC) 
126 (aCGH) 
Biopsy IHC aCGH IMRT 
21 (aCGH), 
50 (IHC) 
Higher T stage 
Rearrangement not associated with BCR risk after 
IMRT 
Watchful waiting, active surveillance, and ADT cohorts 
Attard et al [30] 445 TURP FISH WW 30 
Higher Gleason score, higher 
stage, higher PSA 
Rearrangement independent predictor of poor DSS and 
OS 
Demichelis et al [31] 111 TURP FISH WW 15 Higher Gleason score 
Rearrangement associated with higher risk of metastatic 
progression and PCa death in univariate analysis 
Hägglöf et al [32] 350 TURP IHC WW 40 
Higher Gleason score and higher 
PSA 
ERG IHC positivity independently predictive of poor DSS 
Qi et al[33] 224 TURP FISH/IHC WW 23 Higher PSA 
Rearrangement/ERG IHC positivity independently 
associated with PCa death risk (HR: 2.1) 
Bismar et al [34] 152 (no. TURP IHC AS/RP/EBRT 26 Higher Gleason score and higher ERG IHC positivity associated with longer time to CRPC 
Table
1); 160 
(no. 2) 
(no. 1), ADT 
(no. 2) 
tumor volume among androgen-deprived patients 
Boormans et al [35] 85 
Node 
metastas
is 
TURP 
RT-PCR ADT 59 No 
Rearrangement was not associated with duration of ADT 
response or outcome  
Leinonen et al [36] 178 Biopsy FISH ADT 34 
Ki-67 proliferation index, age, 
and tumor volume 
Rearrangement not associated with disease progression 
Berg et al [37] 265 Biopsy IHC AS 38 
Higher tumor volume in biopsies 
and higher clinical stage 
ERG positivity independently associated with progression 
risk (HR: 2.45) 
Lin et al [38] 387 Urine RT-PCR AS NA 
Higher Gleason score and higher 
tumor volume 
Urine-detected rearrangement associated with positive 
repeat biopsy  
 
aCGH = array comparative genomic hybridization; ADT = androgen-deprivation therapy; AS = active surveillance; BCR = biochemical recurrence; CRPC = castration-
resistant prostate cancer; DSS = disease-specific survival; FISH = fluorescence in situ hybridization; HR = hazard ratio; IHC = immunohistochemistry; IMRT = 
intensity-modulated radiation therapy; NA = not applicable; NR = not reported; OS = overall survival; PCa = prostate cancer; PSA = prostate-specific antigen; RT-
PCR = reverse transcriptase polymerase chain reaction; RP = radical prostatectomy; SNP = single nucleotide polymorphism; TURP = transurethral resection of 
prostate; WW = watchful waiting. 
 
Table 2 Ȃ Studies investigating association of PTEN mutations and outcome of prostate cancer 
 
Study No. of cases Tissue type 
Detection 
method 
Mutation/Negative IHC 
staining rate, % 
PTEN mutation and association 
with clinical parameters 
Main results 
Leinonen et al 
[45] 
326 (RP), 166 (ADT), 
177 (CRPC), 32 
(CRPC mets) 
RP, biopsy, 
TURP, autopsy 
IHC 
15 (RP) 
45 (CRPC) 
67 (CRPC mets) 
NR 
PTEN loss more frequent in CRPC than RP 
specimens. PTEN loss associated with shorter PFS 
in ERG-positive cases 
Yoshimoto et al 
[46] 
125 RP FISH 45 NR 
Homozygous PTEN deletion independently 
associated with BCR risk. Significant prognostic 
association between ERG and PTEN 
Krohn et al [47] 4699 (RP), 57 (CRPC) 
RP, CRPC 
(TURP) 
FISH/IHC 
Deletion (20) 
Negative/Weak IHC (30) 
Advanced stage, high Gleason 
score, lymph node metastasis, and 
positive surgical margin 
PTEN loss independent predictor of poorer PFS. 
ERG status did not affect predictive value of PTEN 
Reid et al [48] 
308 (conservative 
management) 
TURP FISH 17 
Advanced stage, high Gleason 
score, lymph node metastasis, and 
positive surgical margin 
PTEN loss alone not predictive, but patients with 
PTEN loss and normal ERG status had significantly 
poorer PCa survival 
McCall et al [49] 
68 matched 
castration sensitive 
and resistant 
TURP FISH/IHC 
23 (castration sensitive) 
52 (CRPC) 
No 
Low PTEN staining in IHC associated with poor 
PCa-specific survival among castration-sensitive 
cases 
 
ADT = androgen deprivation therapy; BCR = biochemical recurrence; CRPC = castration-resistant prostate cancer; FISH = fluorescence in situ hybridization; IHC = 
immunohistochemistry; mets = metastases; NR = not reported; PCa = prostate cancer; PFS = progression-free survival; RP = radical prostatectomy; TURP = 
transurethral resection of prostate. 
 
 
Table
Table 3 Ȃ Studies investigating predictive value of gene/expression panels in prostate cancer 
 
Study No. of cases 
Tissue 
type 
No. of 
genes 
analyzed 
No. of 
genes in 
final set 
End point 
Mean 
follow-up, 
yr 
Main results 
Commercial 
application 
Discovery studies  
Cuzick et al [51]  
366 (RP) 
337 (TURP) 
RP TURP 126 31 
BCR (RP) DSS 
(TURP) 
9.4/9.8  
Expression panel independently predictive for BCR (RP) or PCa 
mortality (TURP, conservative management) 
Prolaris 
Erho et al [53]  
Discovery (n = 
359) 
Validation (n = 
186)  
RP NR 22 Metastatic PFS 16.9 
Nested case-control study (cases with metastasis, controls with 
or without PSA relapse after RP). Expression panel had AUC of 
0.75 (validation) for prediction of metastasis 
Decipher 
Talantov et al 
[57]  
Discovery (n = 
138) 
Validation (n = 
158) 
RP 1200 3 BCR 6.0 
BCR risk after RP. Predictive value of combined expression and 
Kattan postoperative nomogram better than clinical 
nomogram alone (AUC 0.77 vs 0.67) 
No 
Sboner et al [63]  
Discovery (n = 
186) 
Validation (n = 90) 
TURP 6100 18 DSS ηͳͲ Case-control study (indolent vs lethal PCa in WW cohort). Expression panel not better than clinical model predicting 
outcome 
No 
Irshad et al [62]  
Discovery, 2 sets (n 
= 29/25) 
Validation, 2 sets 
(n = 131/28) 
Various 377 3 BCR NA 
Several discovery cohorts validated in TURP WW cohorts. 
Three-gene model had better prediction (AUC: 0.86) than 
Gleason (0.82) or DǯAmico classification (AUC: 0.72)  No 
Gasi Tandefelt et 
al [42]  
Discovery (n = 48) 
Validation (n = 
127) 
RP NR 36 BCR 10 
BCR risk analysis after RP. Expression panel predictive for BCR 
risk, but only in subgroup of ERG fusion-positive cases 
No 
Penney et al [64]  
358 (TURP) 
109 (RP/TURP) 
TURP RP 6100 157 DSS ηͳͲ Expression panel improved prediction of PCa mortality among 
Gleason 7 cases after conservative management or RP 
No 
Nakagawa et al 
[59]  
Three sets; n = 213 
in each 
RP 1021 17 MFS, DSS NR 
Case-control study (systemic progression vs PSA relapse only 
vs no evidence of disease after RP). Expression panel 
predictive of systemic progression and DSS 
No 
Wu et al [52] 
Discovery (n = 
209) 
Validation (n = 
306) 
RP 1536 32 BCR, MFS 12.7 
Expression panel offered independent predictive value and 
improved postoperative nomograms in prediction of BCR and 
freedom from metastasis after RP 
No 
Table
Chen et al [58] 
Discovery (n = 78) 
Validation (n = 79) 
RP 22 283 7 BCR 4.3 Seven-gene panel predictive of BCR in univariate analysis No 
Cheville et al 
[60]  
n = 157 RP 38 
2 (with ERG 
and 
aneuploidy) 
MFS and DSS NR 
Case-control study (metastasis/PCa death within 5 yr after RP 
vs no events, matched for Gleason/TNM/PSA/SM status). 
Expression panel had AUC of 0.81 (validation: 0.79) for 
prediction of metastasis or PCa death 
No 
External validation studies 
Cooperberg et al 
[65]  
413 
353 (second 
validation) 
RP NA 31 BCR 7.1 
CCP score independent predictor of BCR after RP. 
Combined genetic and clinical CAPRA score 
outperformed individual scores 
Prolaris 
Bishoff et al [67] 
Set 1 (283) 
Set 2 (176) 
Set 3 (123) 
Bx  NA 31 BCR MFS 
5.1 (1) 
7.3 (2) 
11.0 (3) 
Validation of expression panel from biopsies among 
patients undergoing RP. Panel independent predictor of 
BCR and strongest predictor of metastatic progression in 
univariate analyses  
Prolaris 
Cuzick et al [66] 349 Bx NA 31 DSS 11.8 
Conservatively managed cohort. Expression panel 
strongest predictor of DSS when compared with clinical 
parameters 
Prolaris 
Freedland et al 
[69]  
141 Bx NA 31 BCR DSS 4.8 
From biopsies to predict failure after EBRT. Gene panel 
improved predictive value when added to clinical 
parameters 
Prolaris 
Cooperberg et al 
[61]  
185 RP NA  22 DSS 6.4 
Case-control study (high risk PCa, PCa death vs no PCa 
death). Combined high CAPRA and CCP scores predict 
high risk for PCa death 
Decipher 
Ross et al [71] 85 RP NA 22 MFS NR 
Case-control study (BCR after RP, followed by metastasis 
vs no metastasis). Expression panel more predictive than 
clinical nomograms both in ROC analysis (AUC: 0.82) and 
decision-curve analysis 
Decipher 
Karnes et al [72] 219 RP NA 22 MFS 6.7 
Case-cohort study to validate 22-gene expression panel 
for high-risk RP patients. AUC: 0.79 for 5-yr metastasis 
risk  
Decipher 
Den et al [73] 139 RP NA  22 BCR, MFS 7.4 
Radiation patients after RP (pT3 or positive SMs). 
Expression panel independent predictor of BCR and 
metastasis risk. Additive predictive value when genetic 
and clinical models combined 
Decipher 
Klein et al [54] 
Set 1(n = 441) 
Set 2 (n = 167) 
Set 3 (n = 395) 
RP (1 and 
3) 
Bx (2) 
727 17 
MFS (1), 
adverse RP 
pathology (2 
and 3) 
NR 
Expression panel independently predicted adverse RP 
pathology (high grade/high stage) from biopsies. 
Inclusion of expression panel improved net benefit when 
combined with CAPRA in decision-curve analysis 
Oncotype DX 
Cullen et al [76] 431 Bx NA 17 
Adverse RP 
pathology 
BCR 
5.2 
Test associated with BCR risk in univariate analysis and 
after adjusting for NCCN risk groups 
Oncotype DX 
 
AUC = area under the curve; BCR = biochemical recurrence; Bx = biopsy; CAPRA = Cancer of the Prostate Risk Assessment; CCP = cell cycle progression; DSS = 
disease-specific survival; EBRT = external beam radiation; MFS = metastasis-free survival; NA = not applicable; NCCN = National Comprehensive Cancer Network; 
NR = not reported; OS = overall survival; PCa = prostate cancer; PSA = prostate-specific antigen; RP = radical prostatectomy; SM = surgical margin; TURP = 
transurethral resection of prostate; WW = watchful waiting. 
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Illustration
Instructions to typesetter for EURUROL-D-15-00217 
 
Figure 1 
-Lowercase and italicize n, insert space before and after equals signs (eg, n = 1218) 
-Insert comma after Scopus 
-Change Additional Studies to: Additional studies; change publication to: publications 
-Change non-english to: non-English 
-Change Non-relevant to: Nonrelevant 
-Change Records, excluded [twice] to: Records excluded 
Illustration
